Literature DB >> 17908947

In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.

Frances L Clouse1, Laurie B Hovde, John C Rotschafer.   

Abstract

This study compared the ability of telavancin to the ability of cefazolin and vancomycin to eliminate staphylococci from peritoneal dialysis fluid by using a static in vitro model to simulate the conditions of peritoneal dialysis. The results showed that telavancin exhibited statistically significantly better kill (P < 0.05) against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17908947      PMCID： PMC2167995          DOI： 10.1128/AAC.00435-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors:  J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  Peritoneal dialysis-related infections recommendations: 2005 update.

Authors:  Beth Piraino; George R Bailie; Judith Bernardini; Elisabeth Boeschoten; Amit Gupta; Clifford Holmes; Ed J Kuijper; Philip Kam-Tao Li; Wai-Choong Lye; Salim Mujais; David L Paterson; Miguel Perez Fontan; Alfonso Ramos; Franz Schaefer; Linda Uttley
Journal:  Perit Dial Int       Date:  2005 Mar-Apr       Impact factor: 1.756

3.  Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat.

Authors:  R M Cozens; E Tuomanen; W Tosch; O Zak; J Suter; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids.

Authors:  Sheryl Zelenitsky; Christine Franczuk; Adrian Fine; Robert Ariano; Godfrey Harding
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

5.  Growth of coagulase negative staphylococci in peritoneal dialysate fluid. Effect of calcium concentration.

Authors:  A R Morton; G Evans; A Shannon; D Zoutman
Journal:  ASAIO J       Date:  1994 Jul-Sep       Impact factor: 2.872

6.  The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.

Authors:  E Tuomanen; R Cozens; W Tosch; O Zak; A Tomasz
Journal:  J Gen Microbiol       Date:  1986-05

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; John R Hotchkiss; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study.

Authors:  R Selgas; M J Fernandez-Reyes; E Bosque; M A Bajo; F Borrego; C Jimenez; G Del Peso; F De Alvaro
Journal:  Am J Kidney Dis       Date:  1994-01       Impact factor: 8.860

10.  Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions.

Authors:  W A McDonald; J Watts; M I Bowmer
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948
  10 in total
  4 in total

1.  Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids.

Authors:  S Tobudic; W Poeppl; C Kratzer; A Vychytil; H Burgmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-19       Impact factor: 3.267

Review 2.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

3.  Current and novel antibiotics against resistant Gram-positive bacteria.

Authors:  Federico Perez; Robert A Salata; Robert A Bonomo
Journal:  Infect Drug Resist       Date:  2008-09-09       Impact factor: 4.003

4.  Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.

Authors:  Terry King-Wing Ma; Chi Bon Leung; Kai Ming Chow; Bonnie Ching-Ha Kwan; Philip Kam-Tao Li; Cheuk Chun Szeto
Journal:  Clin Kidney J       Date:  2016-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.